Sanofi-aventis video Q&A: CFO Jérôme Contamine Comments on Results for Q3 2010

PARIS PARIS--(BUSINESS WIRE)-- Sanofi-aventis (Paris:SAN) (NYSE:SNY), one of the world’s largest diversified healthcare companies, reports results for the third-quarter of 2010. Jérôme Contamine, Chief Financial Officer of sanofi-aventis, comments on earnings and outlook.

Click to watch the video:

http://www.eurobusinessmedia.com/Sanofi-aventis-video-Q-A-CFO-Jerome-Contamine-comments-on-Q3-2010-results

Topics covered in the interview include:

  • Q3 earnings
  • 2010 full year guidance
  • Lovenox®
  • New launches (Jevtana®, Multaq®)
  • Seasonal flu vaccines
  • Eloxatin®
  • lixisenatide for Diabetes
  • teriflunomide for Multiple Sclerosis
  • US healthcare reform and EU price cuts
  • Cost savings
  • Patent cliff

About sanofi-aventis:

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Company website: http://en.sanofi-aventis.com/home.asp



CONTACT:

Investor Relations : [email protected]
or
Media Relations : [email protected]

KEYWORDS:   Europe  France

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.